fbpx

molecules of the month

DS96432529

oral CDK8 kinase inhibitor

effective in ovariectomized rat model

CDK8 identified as MoA after screen

Bioorganic & Medicinal Chemistry Letters

Daiichi Sankyo Co. Ltd.

Chemical structure of molecule DS96432529 Daiichi Sankyo CDK8 kinase inhibitor
1 min read

7.     The Daiichi Sankyo CDK8 kinase inhibitor, DS96432529, is intended to be a bone anabolic agent. The molecule shows preclinical efficacy and synergy with alendronate or parathyroid hormone. The discovery program was initiated well before the likely target (CDK8) was identified and provides an interesting retrospective case study for phenotypic drug discovery.


request a trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more.

Interested in learning more? Submit this form to request a trial.


already a member? log in: